Abilify, a schizophrenia drug sold by Bristol in the U.S., was invented by Japan's Otsuka .
Both doctors say Abilify doesn't seem to cause weight gain or many other side effects.
Abilify could be a breakthrough in treating schizophrenia, but Bristol's accounting is still a mess.
The exception is Abilify, a schizophrenia drug that may cause less weight gain than some competitors do.
But the new medicine, Abilify, could represent a breakthrough for the 2.4 million Americans suffering from schizophrenia.
By making the dopamine thermostat more normal, Abilify seems to treat the second set of symptoms as well.
Abilify isn't as powerful as Zyprexa, but it seems to have fewer side effects, including causing less weight gain.
FORBES: Bristol's Earnings Restatement: Prelude To A Merger?
They say Abilify is a new kind of schizophrenia medicine--only the third such advance in more than 50 years.
Abilify and Risperdal are approved for treating children with schizophrenia and bipolar disorder.
Abilify, a schizophrenia medicine launched in the fall, seems to be taking hold, with 4% of new prescriptions each week.
But Bristol-Myers also received a piece of good news: Its new schizophrenia drug, Abilify, has got a key competitor worried.
FORBES: Bristol's Earnings Restatement: Prelude To A Merger?
They include Abilify for schizophrenia and bipolar disorder, Reyataz for HIV, Orencia for rheumatoid arthritis and Sprycel for chronic myelogenous leukemia.
Abilify was approved by the U.S. Food and Drug Administration on Friday and could be in pharmacies two weeks from now.
Still, Abilify's prospects offer little comfort for investors who bought Bristol when it was booking what appeared to be relatively healthy earnings.
Aside from Reyataz, Bristol is relying heavily on Abilify, the antipsychotic medicine it sells through an agreement with Japan's Otsuka Pharmaceuticals .
Abilify sticks to the receptor but does not shut it off entirely.
Like Abilify, bifeprunox was supposed to be an option that did not cause severe weight gain for schizophrenics and other mentally ill patients.
Bristol will be increasing the sales-force support for Abilify by 50%, Dolan said, and sales are as good or better than Bristol hoped.
But Evans points out that Abilify may be suffering because it is marketed just to psychiatrists, who represent only about 60% of the market.
It recently received approval from the U.S. Food and Drug Administration for a promising schizophrenia drug, Abilify, that was invented by Japan's Otsuka Pharmaceuticals.
Abilify, from Otsuka and Bristol-Myers Squibb, passed Seroquel from Astra as the top-selling antipsychotic drug for disease like schizophrenia, bipolar disorder, and depression.
But Abilify could become the first choice for young patients who are being diagnosed for the first time with mild to moderate schizophrenia symptoms.
Abilify, a schizophrenia medicine from Bristol-Myers Squibb (nyse: BMY - news - people ) and Japan's Otsuka, is also gaining ground fast.
Abilify's side-effect profile is a thorn in the side of market leader Zyprexa, from Eli Lilly (nyse: LLY - news - people ).
Although they are called "antipsychotics, " these agents (for example Seroquel, Abilify, Zyprexa) are also widely used to help with severe depression and anxiety and are often quite effective.
As with other compulsive behaviors like gambling and drinking, Delmonico recommends therapy and 12-step programs, although antidepressants (drugs llike Paxil or Zoloft) and antipsychotics like (these include Abilify and Zyprexa) may help.
These later trials could also shed some light on the effectiveness of Abilify, from Otsuka Pharmaceuticals and Bristol-Myers Squibb (nyse: BMY - news - people ), which, like Geodon, is touted as causing less weight gain.
Eli Lilly (nyse: LLY - news - people ) said yesterday that it expects sales growth of its schizophrenia drug, Zyprexa, to slump into the single digits if Abilify is approved in the fourth quarter of this year.
FORBES: Bristol's Earnings Restatement: Prelude To A Merger?
Sales of Risperdal, a schizophrenia medicine, grew only 1% in the U.S., Weinstein says, slowed by competition from Abilify, a new antipsychotic made by Bristol-Myers Squibb (nyse: BMY - news - people ) with a very clean safety profile.
Bristol may be dressing itself up for sale, it will lose its two top products (Plavix for heart disease and Abilify for mental illness) within four years, and ImClone's pipeline of experimental drugs contains two threats to Erbitux sales that ImClone controls outright.
应用推荐